For immediate release: July 31, 2019
Boston, MA – Children born with HIV in the U.S. were less likely to adhere to their medications as they aged from preadolescence to adolescence and into young adulthood, according to a new study led by researchers at Harvard T.H. Chan School of Public Health. Additionally, the prevalence of detectable viral load—an indication that the virus is not being managed by medications and a factor that’s often associated with nonadherence—also increased with age.
The study is one of the first to examine why different age groups stop adhering to treatment. While the factors related to nonadherence varied by age group, youth who were concerned about side effects of the drugs were less likely to be adherent at most ages.
“As they approach adulthood, many youth face challenges, such as entering new relationships, managing disclosure of their HIV status, and changing to an adult HIV care provider. Ensuring successful HIV medication adherence before and throughout adolescence is critical,” said lead author Deborah Kacanek, research scientist in Harvard Chan School’s Department of Biostatistics. “We found that the factors that either supported adherence and a suppressed (undetectable) viral load, or made it harder for youth to adhere to treatment, varied depending on their age.”
The study was published online ahead of print in AIDS.
In the U.S., approximately 12,000 children, adolescents, and young adults are living with perinatally acquired HIV, meaning that they have lived with HIV since birth. Globally, 1.8 million adolescents live with HIV. Adhering to regimens of antiretroviral therapy (ART) is key to managing the disease and reducing the risk of transmission. Sticking to a daily regimen of medicine, however, is especially challenging for adolescents and young adults, who are navigating a range of physical, cognitive, social, and emotional changes.
Adherence can be more complicated for youth growing up with perinatal HIV, whose lifelong experiences with HIV, stigma, and multiple antiretroviral medications may pose challenges to achieving viral suppression that are different from youth who acquire HIV later in life.
To better understand these challenges and why young people may not adhere to their medications, researchers followed 381 youth with perinatally acquired HIV for an average of 3.3 years. The youth were participants in the Pediatric HIV/AIDS Cohort Study, which follows children and youth born with HIV or born exposed at birth to HIV to determine the impact of lifelong HIV and the long-term safety of antiretroviral regimens.
The preadolescents, adolescents, and young adults in the study ranged from age 8 to 22 and were recruited from 15 different clinical sites in the U.S, including Puerto Rico. As part of the study, the researchers examined results from blood tests that measured viral loads, and they examined nearly 1,200 adherence evaluations in which study participants or their caregivers self-reported any missed doses of medication in the prior seven days.
The researchers found that from preadolescence to young adulthood, the prevalence of nonadherence increased from 31% to 50%. In addition, the prevalence of detectable viral load among the same age groups increased from 16% to 40%.
For each age group, different factors were associated with nonadherence. For example, during middle adolescence (15-17 years old), alcohol use, having an unmarried caregiver, indirect exposure to violence, stigma, and stressful life events were all associated with nonadherence.
“It is important to talk with youth about how to take medications properly, but our study highlights the need for those who care for these youths to focus also on age-related factors that may influence adherence,” Kacanek said. “Services to help support adherence need to address both the age-related risks and build on the sources of strength and resilience among youth at different stages of development.”
Other Harvard Chan School researchers who contributed to the study include Claire Berman, Yanling Huo, and Katherine Tassiopoulos.
Funding for this study came from Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute on Drug Abuse, the National Institute of Allergy and Infectious Diseases, the Office of AIDS Research, the National Institute of Mental Health, the National Institute of Neurological Disorders and Stroke, the National Institute on Deafness and Other Communication Disorders, the National Institute of Dental and Craniofacial Research, and the National Institute on Alcohol Abuse and Alcoholism.
“Nonadherence and unsuppressed viral load across adolescence among US youth with perinatally acquired HIV,” Deborah Kacanek, Yanling Huo, Kathleen Malee, Claude A. Mellins, Renee Smith, Patricia A. Garvie, Katherine Tassiopoulos, Sonia Lee, Claire Berman, Mary Paul, Ana Puga, Susannah Allison, for the Pediatric HIV/AIDS Cohort Study (PHACS), AIDS, online July 3, 2019, doi: 10.1097/QAD.0000000000002301
For more information:
Harvard T.H. Chan School of Public Health brings together dedicated experts from many disciplines to educate new generations of global health leaders and produce powerful ideas that improve the lives and health of people everywhere. As a community of leading scientists, educators, and students, we work together to take innovative ideas from the laboratory to people’s lives—not only making scientific breakthroughs, but also working to change individual behaviors, public policies, and health care practices. Each year, more than 400 faculty members at Harvard Chan School teach 1,000-plus full-time students from around the world and train thousands more through online and executive education courses. Founded in 1913 as the Harvard-MIT School of Health Officers, the School is recognized as America’s oldest professional training program in public health.